Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SNRPA CRISPR/Cas9 KO Plasmid (h): sc-404128
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SNRPA CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SNRPA genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SNRPA Antibody (B-12): sc-376027
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SNRPA CRISPR/Cas9 KO Plasmid (h) | sc-404128 | 20 µg | $397.00 |
Overview
SNRPA encodes the U1 small nuclear ribonucleoprotein A, an essential core component of the U1 snRNP that recognizes 5′ splice sites during pre-mRNA splicing. By participating in early spliceosome assembly, SNRPA supports accurate intron removal, transcript maturation, and coordination of gene-expression programs coupled to transcription and RNA processing. Disruption of U1 snRNP function can drive widespread alternative splicing and transcript instability, processes frequently implicated in oncogenic transformation and neurodevelopmental and neurodegenerative phenotypes. As a foundational spliceosomal factor, SNRPA is commonly studied to connect splicing fidelity with proteostasis, cell-cycle control, and stress-responsive RNA regulatory networks.
SNRPA CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SNRPA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SNRPA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SNRPA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SNRPA protein expression.
This CRISPR knockout system enables efficient generation of SNRPA-deficient cell models for investigation of SNRPA signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SNRPA exon(s) critical for SNRPA function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SNRPA genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SNRPA CRISPR/Cas9 KO Plasmid (h) and SNRPA CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SNRPA locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SNRPA HDR Plasmid (h) and SNRPA HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SNRPA homology arms to support homology-directed repair at defined SNRPA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.